NASDAQ · NXGL

NEXGEL, Inc.

Healthcare · Medical - Instruments & Supplies

$0.27▲ 5.29% ($0.01)at close

As of 4:00 PM ET

52-week

$0.24$2.89

Market cap

$2.33M

P/E

-0.39

EPS (TTM)

-$0.69

Next earnings

Nov 10, 2026

What the market price implies · Reverse DCF

Historical revenue grew by 64.73%/yr over the past 4 years.

Selected forecast · Base scenario

19.61%/yr · actual 10-year annualized revenue growth

Year 1 growth: 40%

Market-implied · Base operating assumptions + edited margins

Unavailable · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

No supported revenue growth rate matches this price with these operating assumptions.

Valuation

Recommended · Revenue & margin DCF

Price used

$0.27

Estimated value / share

Unavailable

Base scenario

USD · TTM ending 2026-06-30

More than 85% of this valuation sits in the terminal value beyond year 10, so the result is driven by the perpetuity assumption rather than the projected decade. The valuation is not shown.

Year 1 growth 40% · Ending margin 0% · Discount rate 6.03%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 22, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 22, 2026, 9:20 PM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Likely fundamental deteriorationModerate confidence

1Y Price: -89.14%Revenue (TTM): 3.38%FCF (TTM): -9.58%P/S: 0th pct

What changed

The stock fell 89.14% over the last year. Revenue grew 3.38% over the trailing twelve months. Operating margin moved from -26.06% to -44.77%. Free cash flow declined 9.58% over the trailing twelve months.

What the market seems to be pricing

The market is reacting to weaker business momentum more than just compressing the valuation multiple. Even if the shares already screen cheap on P/S, investors are still discounting lower future earnings power.

What would invalidate this read

Operating margin stands at -44.77%. Free cash flow fell 9.58% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.

Performance

Return analysis

Company profile

NEXGEL, Inc. is a company that develops and produces advanced hydrogels and gels.

CEOBrian J. Kieser

SectorHealthcare

IndustryMedical - Instruments & Supplies

Employees19

IPO dateDec 22, 2021

https://nexgel.com

Market multiples

Forward P/E—

EV/EBITDA-7.28

Enterprise value$15.42M

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth27.81%

Gross margin (FY2025)39.48%▲7.9ppvs FY2024

Operating margin (FY2025)-29.35%▲11.6ppvs FY2024

ROE-128.59%▼69.8ppvs FY2025

Analyst consensus

RatingHold

Target price—

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 10, 2026

Q4 FY26 · EPS est -$0.24 · Revenue est $4.19M

View

NASDAQ · NXGL

NEXGEL, Inc.

Healthcare · Medical - Instruments & Supplies

$0.27▲ 5.29% ($0.01)at close

As of 4:00 PM ET

52-week

$0.24$2.89

Market cap

$2.33M

P/E

-0.39

EPS (TTM)

-$0.69

Next earnings

Nov 10, 2026

What the market price implies · Reverse DCF

Historical revenue grew by 64.73%/yr over the past 4 years.

Selected forecast · Base scenario

19.61%/yr · actual 10-year annualized revenue growth

Year 1 growth: 40%

Market-implied · Base operating assumptions + edited margins

Unavailable · flat 10-year annualized revenue growth

No supported revenue growth rate matches this price with these operating assumptions.

Valuation

Recommended · Revenue & margin DCF

Price used

$0.27

Estimated value / share

Unavailable

Base scenario

USD · TTM ending 2026-06-30

More than 85% of this valuation sits in the terminal value beyond year 10, so the result is driven by the perpetuity assumption rather than the projected decade. The valuation is not shown.

Year 1 growth 40% · Ending margin 0% · Discount rate 6.03%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 22, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 22, 2026, 9:20 PM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Likely fundamental deteriorationModerate confidence

1Y Price: -89.14%Revenue (TTM): 3.38%FCF (TTM): -9.58%P/S: 0th pct

What changed

What the market seems to be pricing

What would invalidate this read

Performance

Return analysis

Company profile

NEXGEL, Inc. is a company that develops and produces advanced hydrogels and gels.

CEOBrian J. Kieser

SectorHealthcare

IndustryMedical - Instruments & Supplies

Employees19

IPO dateDec 22, 2021

https://nexgel.com

Market multiples

Forward P/E—

EV/EBITDA-7.28

Enterprise value$15.42M

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth27.81%

Gross margin (FY2025)39.48%▲7.9ppvs FY2024

Operating margin (FY2025)-29.35%▲11.6ppvs FY2024

ROE-128.59%▼69.8ppvs FY2025

Analyst consensus

RatingHold

Target price—

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 10, 2026

Q4 FY26 · EPS est -$0.24 · Revenue est $4.19M

View